Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders. (November 2022)

• Record Type: Journal Article
• Authors: Saraceno, Lorenzo; Pirro, Fiammetta; Stigliano, Rosa; Agostoni, Elio Clemente; Protti, Alessandra
• Is Part Of: Multiple sclerosis. Volume 28:Number 13(2022)
• Page Start: 2142
• Page End: 2145
• Publication Date: 2022-11
• Subjects: Cladribine -- multiple sclerosis -- liver injury -- idiosyncratic drug-induced liver injury -- DILI -- hepatitis; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585221125360
• Languages: English
• ISSNs: 1352-4585

Abstract

In recent years, several disease-modifying therapies have been developed for the treatment of multiple sclerosis (MS). Cladribine transiently depletes B and T lymphocytes, with subsequent gradual cell recovery. No cases are reported in literature describing Cladribine drug-induced liver injury (DILI). We describe the case of a 19-year-old woman who developed acute idiosyncratic liver injury 12 days after treatment with Cladribine. Post-marketing adverse event reporting is of paramount importance to allow an early recognition and treatment. Moreover, evaluation of the physiopathological mechanism underlying drug-induced hepatic toxicity can provide clinicians with valuable instruments for prevention and treatment.